STUDY SPACE
Pancreatic Adenocarcinoma, Version 2.2017

Pancreatic Adenocarcinoma, Version 2.2017

August 2017 | Margaret A. Tempero, MD; Mokenge P. Malafa, MD; Mahmoud Al-Hawary, MD; Horacio Asbun, MD; Andrew Bain, MD; Stephen W. Behrman, MD; Al B. Benson III, MD; Ellen Binder, MD; Dana B. Cardin, MD; Charles Cha, MD; E. Gabriela Chiorean, MD; Vincent Chung, MD; Brian Czito, MD; Mary Dillhoff, MD; Efrat Dotan, MD; Cristina R. Ferrone, MD; Jeffrey Hardacre, MD; William G. Hawkins, MD; Joseph Herman, MD, MSc; Andrew H. Ko, MD; Srinadh Komanduri, MD; Albert Koong, MD, PhD; Noelle LoConte, MD; Andrew M. Lowy, MD; Cassadie Moravek, MD; Eric K. Nakakura, MD; Eileen M. O’Reilly, MD; Jorge Obando, MD; Sushanth Reddy, MD; Courtney Scaife, MD; Sarah Thayer, MD, PhD; Colin D. Weekes, MD, PhD; Robert A. Wolff, MD; Brian M. Wolpin, MD, MPH; Jennifer Burns; and Susan Darlow, PhD
The NCCN Guidelines for Pancreatic Adenocarcinoma provide recommendations for the diagnosis, treatment, and management of pancreatic cancer. These guidelines emphasize the importance of multidisciplinary evaluation, including imaging, surgery, radiation therapy, and systemic therapy. High-quality multiphase imaging is used to preoperatively determine resectability. Systemic therapy is used in neoadjuvant, adjuvant, and metastatic settings. Clinical trials are critical for advancing treatment options. The guidelines categorize evidence and recommendations, with category 2A being the default unless otherwise noted. The guidelines recommend participation in clinical trials for cancer patients. Diagnosis involves imaging, endoscopic ultrasound, and biopsy. Biomarkers such as CA 19-9 are used for staging and monitoring. Systemic therapy options include gemcitabine, FOLFIRINOX, and combinations with other chemotherapeutic agents. The guidelines also address the use of neoadjuvant and adjuvant therapies, as well as palliative care. The NCCN Panel emphasizes the importance of multidisciplinary care and the need for further research to improve outcomes for patients with pancreatic cancer.The NCCN Guidelines for Pancreatic Adenocarcinoma provide recommendations for the diagnosis, treatment, and management of pancreatic cancer. These guidelines emphasize the importance of multidisciplinary evaluation, including imaging, surgery, radiation therapy, and systemic therapy. High-quality multiphase imaging is used to preoperatively determine resectability. Systemic therapy is used in neoadjuvant, adjuvant, and metastatic settings. Clinical trials are critical for advancing treatment options. The guidelines categorize evidence and recommendations, with category 2A being the default unless otherwise noted. The guidelines recommend participation in clinical trials for cancer patients. Diagnosis involves imaging, endoscopic ultrasound, and biopsy. Biomarkers such as CA 19-9 are used for staging and monitoring. Systemic therapy options include gemcitabine, FOLFIRINOX, and combinations with other chemotherapeutic agents. The guidelines also address the use of neoadjuvant and adjuvant therapies, as well as palliative care. The NCCN Panel emphasizes the importance of multidisciplinary care and the need for further research to improve outcomes for patients with pancreatic cancer.
Terms of Service
Privacy Policy
Reach us at info@study.space
Understanding Pancreatic Adenocarcinoma%2C Version 2.2017%2C NCCN Clinical Practice Guidelines in Oncology.